<DOC>
	<DOCNO>NCT00763815</DOCNO>
	<brief_summary>The purpose study evaluate benefit risk lixisenatide ( AVE0010 ) , comparison placebo , add-on treatment pioglitazone without metformin , period 24 week treatment , follow extension . The primary objective ass effect lixisenatide add pioglitazone glycemic control term glycosylated hemoglobin ( HbA1c ) reduction ( absolute change ) Week 24 . Secondary objective assess effect lixisenatide add pioglitazone percentage patient reach HbA1c le 7 percent ( % ) less equal 6.5 % , fast plasma glucose ( FPG ) , body weight , beta-cell function ( assess homeostatic model assessment beta-cell function [ HOMA-beta ] ) , fast plasma insulin ( FPI ) , assess safety , tolerability , pharmacokinetics ( PK ) anti-lixisenatide antibody development .</brief_summary>
	<brief_title>GLP-1 Receptor Agonist Lixisenatide Patients With Type 2 Diabetes Glycemic Control Safety Evaluation , Top Pioglitazone</brief_title>
	<detailed_description>Patients complete 24-week main double-blind treatment would undergo variable double-blind extension treatment , end patient approximately schedule date Week 76 visit ( Visit 25 ) last randomized patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus , diagnose least 1 year time screen visit , insufficiently control pioglitazone HbA1c le ( &lt; ) 7 percent ( % ) great ( &gt; ) 10 % screen At time screen age &lt; legal age majority Pregnant breastfeed woman woman childbearing potential without effective contraceptive method birth control Type 1 diabetes mellitus Pioglitazone stable dose least 30 milligram per day ( mg/day ) least 3 month prior screen If treatment metformin , stable dose least 1.5 gram per day ( g/day ) least 3 month prior screen visit FPG screen &gt; 250 milligram per deciliter ( mg/dL ) ( &gt; 13.9 millimole per liter [ mmol/L ] ) Body mass index less equal ( &lt; = ) 20 kilogram per square meter ( kg/m^2 ) Weight change 5 kg 3 month precede screen visit History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease History metabolic acidosis , include diabetic ketoacidosis within 1 year prior screen Hemoglobinopathy hemolytic anemia , receipt blood plasma product within3 month prior time screen History myocardial infarction stroke within last 6 month prior screen Known history drug alcohol abuse within 6 month prior time screen Cardiovascular , hepatic , neurological , endocrine disease , active malignant tumor major systemic disease patient short life expectancy make implementation protocol interpretation study result difficult , history presence clinically significant diabetic retinopathy , history presence macular edema likely require laser treatment within study period Uncontrolled inadequately control hypertension time screen rest systolic blood pressure diastolic blood pressure ( DBP ) &gt; 180 millimeter mercury ( mmHg ) &gt; 95 mmHg , respectively Laboratory finding time screening : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) : &gt; 2 time upper limit normal ( ULN ) laboratory range ; amylase and/or lipase : &gt; 3 time ULN ; total bilirubin : &gt; 1.5 time ULN ( except case Gilbert 's syndrome ) ; Hemoglobin &lt; 11 gram/deciliter and/or neutrophil &lt; 1500 per cubic millimeter ( mm^3 ) and/or platelet &lt; 100 000/mm^3 ; positive test Hepatitis B surface antigen ( HBsAg ) and/or Hepatitis C antibody ( HCAb ) ; positive serum pregnancy test female childbearing potential Any clinically significant abnormality identify physical examination , laboratory test , electrocardiogram ( ECG ) , vital sign time screen , judgment investigator subinvestigator , preclude safe completion study constrain efficacy assessment Patients consider investigator subinvestigator inappropriate study reason ( example , impossibility meet specific protocol requirement [ schedule visit , able selfinjections ] ; likelihood require treatment screen phase treatment phase drug permit clinical study protocol ; investigator subinvestigator , pharmacist , study coordinator , study staff relative thereof directly involve conduct protocol ) Use oral injectable antidiabetic hypoglycemic agent metformin pioglitazone ( example , sulfonylurea , alphaglucosidase inhibitor , thiazolidinediones , rimonabant , exenatide , dipeptidyl peptidase4 [ DPP4 ] inhibitor , insulin ) within 3 month prior time screen Use systemic glucocorticoid ( exclude topical application inhale form ) 1 week within 3 month prior time screen Use investigational drug within 3 month prior study Any previous treatment lixisenatide participation previous study lixisenatide Renal impairment define creatinine &gt; 1.4 mg/dL woman creatinine &gt; 1.5 mg/dL men ( applicable patient metformin treatment ) Patients cardiac failure history cardiac failure ( New York Heart Association class I IV ) Endstage renal disease define serum creatinine clearance &lt; 15 milliliter per minute ( mL/min ) ( calculate Cockcroft Gault formula ) and/or patient dialysis , treatment metformin Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include , limited , gastroparesis gastroesophageal reflux disease require medical treatment , within 6 month prior time screen Allergic reaction glucagon like peptide1 ( GLP1 ) agonist past ( example , exenatide , liraglutide ) metacresol Additional exclusion criterion end runin phase : informed consent withdrawal ; lack compliance singleblind placebo runin phase ( &gt; 2 injection miss ) ; patient adverse event precludes inclusion study , assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hyperglycemia GLP-1 pioglitazone</keyword>
</DOC>